loader
Please Wait
Applying Filters...

Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    List of Drug Master Files (DMF) for 23031 Active Pharmaceutical Ingredient (API) submitted to the U.S. FDA. Original Data : FDA Website

    Client Virtual Booth
    Menu

    ALP Pharm

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Aspen API. More than just an API.

    Left Arrow
    Right Arrow
    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 ALP Pharm (1)

    filter

    01 BROENAC SODIUM HYDRATE (1)

    filter

    01 China (1)

    filter

    01 Active (1)

    filter

    01 Complete (1)

    ListList of Suppliers
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us

    ALP PHARM BEIJING CO LTD

    Contact Supplier
      Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
      Post an Enquiry Post an Enquiry
      Flag China
      Virtual Booth Virtual Booth
      Digital Content Digital Content

      BROENAC SODIUM HYDRATE

      PDF Supplier PDF
      URL Supplier Web Content
      23031
      Active
      2009-07-31
      Complete
      2013-05-01
      2013-04-16
      II
      ASK
      US
      PHARMACOMPASS
      Upload
      your Marketing & Sales content

      Looking for Drug Master Files (DMF) for 23031 of Alp Pharm Beijing Co Ltd

      Looking for Drug Master Files (DMF) for 23031 of Alp Pharm Beijing Co Ltd 1

      20

      Alp Pharm Beijing Co Ltd, based in China, is a pharmaceutical company.

      One of their notable products is BROENAC SODIUM HYDRATE, with a corresponding US DMF Number 23031.

      Remarkably, this DMF maintains an Active status since its submission on July 31, 2009, highlighting commitment to regulatory compliance.

      Their GDUFA DMF Review was successfully complete, with a review date of May 01, 2013, and payment made on April 16, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II

      Post Enquiry
      POST ENQUIRY